ArticleThe New England journal of medicine2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Potential Predictors of the Outcome of Tocilizumab Treatment in Patients with COVID-19-Associated Hyperinflammation.Infectious diseases & clinical microbiology · 2025Article
- Effector CD8 T cell differentiation in primary and breakthrough SARS-CoV-2 infection in mice.Communications biology · 2025Article
- Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).Journal of inflammation research · 2025Review
- The usage of immunosuppressant agents and secondary infections in patients with COVID-19 in the intensive care unit: a retrospective study.Scientific reports · 2024Article
- The effect of immunosuppressive therapies on the endothelial host response in critically ill COVID-19 patients.Scientific reports · 2024Article
- Potential marker subset of blood-circulating cytokines on hematopoietic progenitor-to-Th1 pathway in COVID-19.Frontiers in medicine · 2024Article
- Potential Drugs in COVID-19 Management.Current medicinal chemistry · 2024Review
- Targeting IL-6 trans-signalling: past, present and future prospects.Nature reviews. Immunology · 2023Review
- An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature.Scientific reports · 2023Review
- Review
- Article
- Successful Recovery of COVID-19 Associated With Cardiomyopathy in Advanced Breast Cancer Patient With Pulmonary Lymphangitis Carcinomatosis.Clinical medicine insights. Case reports · 2023Article
- Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside.Iranian journal of medical sciences · 2022Review
- Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study.Vaccines · 2022Article
- COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports.Journal of clinical medicine · 2022Review
- Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial.Journal of family medicine and primary care · 2022Article
- Review
- An autopsy case of COVID-19 with a sudden death: Clinico-pathological comparison.Clinical case reports · 2022Article
- A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6Journal of virology · 2022Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34407335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.